

**162.** A pharmaceutical composition comprising immunoconjugates, wherein the immunoconjugates comprise the formula (A)-(L)-(C), wherein:

(A) is an antibody or antigen binding fragment thereof that specifically binds a human folate receptor 1;

(L) is a linker; and

(C) is a cytotoxic agent;

wherein (L) links (A) to (C); and

wherein the antibody or antigen binding fragment thereof comprises:

a HC CDR1 comprising the amino acid sequence of GYFMN (SEQ ID NO:1), a HC CDR2 comprising the amino acid sequence of RIHPYDGDTF (SEQ ID NO:131), and a HC CDR3 comprising the amino acid sequence of YDGSRAMDY (SEQ ID NO:3); and

a LC CDR1 comprising the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:7), a LC CDR2 comprising the amino acid sequence of RASNLEA (SEQ ID NO:8), and a LC CDR3 comprising the amino

acid sequence of QQSREYPYT (SEQ ID NO:9), and wherein the immunoconjugates have an average of 3 to 4 (C) per (A).

**163.** A method for the treatment of cancer comprising administering the immunoconjugate of claim **128** to a subject in need thereof.

**164.** A method for the treatment of cancer comprising administering the pharmaceutical composition of claim **161** to a subject in need thereof.

**165.** The method of claim **164**, wherein the cancer is selected from the group consisting of: ovarian cancer, brain cancer, breast cancer, uterine cancer, pancreatic cancer, renal cancer, cancer of the peritoneum, endometrial cancer, and lung cancer.

**166.** The method of claim **165**, wherein the cancer is endometrial cancer.

**167.** The method of claim **165**, wherein the cancer is ovarian cancer.

**168.** The method of claim **165**, wherein the cancer is cancer of the peritoneum.

\* \* \* \* \*